With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, California-located company discovers, develops, and commercializes medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer, and inflammation. 

Companies worth $10 billion or more are generally described as “large-cap stocks”, and Gilead Sciences fits this criterion perfectly. The company continues to expand its oncology pipeline through strategic acquisitions and partnerships, while maintaining a strong commitment to scientific research and global health impact.

Gilead Sciences stock has dropped nearly 8.9% from its 52-week high of $119.96. Shares of GILD have declined 5.7% in the past three months, underperforming the S&P 500 Index’s ($SPX) 2.1% increase.

In the longer term, Gilead Sciences stock has climbed 18.4% on a YTD basis, whereas SPX has risen 1.5%. Moreover, shares of GILD soared 72.4% over the past 52 weeks, significantly outpacing the SPX's 13% rise over the same time frame.

Despite some fluctuations, the stock has remained above its 50-day and 200-day moving averages since last year.

Gilead Sciences stock fell 2.8% following its weaker-than-expected Q1 2025 results on Apr. 24. The company reported revenue of $6.7 billion, down marginally from the year-ago quarter, and below analysts' estimate of $6.8 billion. The decline in revenue was primarily driven by lower sales of Veklury, cell therapy products, and Trodelvy. Its adjusted EPS stood at $1.81, which missed the consensus. 

Additionally, for fiscal 2025, the company reaffirmed its outlook, expecting product sales between $28.2 billion and $28.6 billion, and adjusted EPS in the range of $7.70 to $8.10. 

In contrast, rival Eli Lilly and Company (LLY) has performed weaker than GILD stock. Shares of LLY have crumbled 9.7% over the past 52 weeks and edged down 2.8% on a YTD basis.

Although GILD has outperformed compared to the broader market over the past year, analysts are cautiously optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 28 analysts covering it, and it is currently trading below the mean price target of $113.08.